BlinkLab (ASX:BB1) said PriMED Clinical Research in Ohio became the first site to join the initial phase of the firm's US-based autism diagnostic registrational trial, according to a Wednesday Australian bourse filing.
The site is expected to commence patient recruitment and testing for the 100-patient study in February.
PriMED will use the overarching institutional review board approval BlinkLab secured for the clinical trial.
The firm is seeking to start initiating partnerships with sixteen sites across the US.
The firm's shares rose 10% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.